Jay Proctor, MD
Family Medicine · Beaumont, TXNPI 1538160726
Payments from drug & device makers
Across 426 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$991
- Amarin Pharma, Inc.$596
- Pfizer$411
- AstraZeneca$351
- GSK$236
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,93599%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 129 | $1,560 |
| Novo Nordisk | 74 | $991 |
| Amarin Pharma, Inc. | 39 | $596 |
| Pfizer | 34 | $411 |
| AstraZeneca | 23 | $351 |
| GSK | 14 | $236 |
| Phathom Pharmaceuticals, Inc. | 12 | $204 |
| Amgen | 11 | $187 |
| Esperion Therapeutics, Inc. | 10 | $156 |
| Merck | 9 | $125 |
| Novartis | 6 | $121 |
| Inspire Medical Systems, Inc. | 3 | $104 |
| Lilly USA, LLC | 6 | $89 |
| Johnson & Johnson | 6 | $72 |
| Daiichi Sankyo Inc. | 4 | $64 |
| Exact Sciences | 4 | $62 |
| Bayer | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Corium, LLC | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Hologic Sales And Service, LLC | 2 | $42 |
| Antares Pharma, Inc. | 3 | $41 |
| Ironwood Pharmaceuticals, Inc | 3 | $38 |
| Eisai Inc. | 3 | $37 |
| Abbott | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Verity Pharmaceuticals Inc. | 2 | $32 |
| Corcept Therapeutics | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Optinose US, Inc. | 2 | $25 |
| Abiomed | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Neos Therapeutics, LP | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $11 |
| Cumberland Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$6,004 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $147,245 |
| FarxigaDapagliflozin Propanediol | 107 | $118,397 |
| MounjaroTirzepatide | 78 | $103,559 |
| Repatha SureclickEvolocumab | 140 | $102,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $70,103 |
| JardianceEmpagliflozin | 74 | $68,894 |
| TrulicityDulaglutide | 44 | $63,354 |
| EliquisApixaban | 41 | $35,100 |
| RybelsusSemaglutide | 19 | $23,168 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $22,798 |
| XareltoRivaroxaban | 26 | $20,859 |
| Repatha SyringeEvolocumab | 23 | $18,690 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $17,945 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $13,446 |
| JanuviaSitagliptin Phosphate | 16 | $13,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $991 | $170,413105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $89 | $166,913122 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $351 | $136,342124 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $33 | $74,37985 claims |
| GSKTrelegy Ellipta | $236 | $70,10372 claims |
| PfizerEliquis | $411 | $35,10041 claims |
| Johnson & JohnsonXarelto | $72 | $20,85926 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $156 | $15,53523 claims |
| MerckJanuvia | $125 | $13,08616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $14 | $3,76713 claims |
| AbbVieSynthroid | $1,560 | $3,650111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Beaumont
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.